The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
LRRK2 activation in idiopathic Parkinson’s disease
Open accessAbstract
Wild-type LRRK2 is activated in nigrostriatal dopamine neurons in idiopathic Parkinson’s disease and plays a pathogenic role in this neurodegenerative disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 1×
“Both chaperone-mediated autophagy (CMA) and macroautophagy play roles in -synuclein degradation (27, 28).”
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. (2016) · eLife · doi:10.7554/elife.12813 · Cited by 1,042
Self-citationKinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Self-citationLRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463
Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010) · Biochemical Journal · doi:10.1042/bj20100784 · Cited by 372
Self-citationSheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., Solanoy, H. O., Drummond, J., Zhang, X., Ding, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004485 · Cited by 353
Betarbet, R., Canet-Aviles, R. M., Sherer, T. B., Mastroberardino, P. G., McLendon, C., Kim, J.-H., Lund, S., Na, H.-M., Taylor, G., Bence, N. F., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.003 · Cited by 342
Self-citationStaging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium
Alafuzoff, I., Ince, P. G., Arzberger, T., Al-Sarraj, S., Bell, J., Bodi, I., Bogdanovic, N., Bugiani, O., Ferrer, I., Gelpi, E., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0523-2 · Cited by 322
Fell, M. J., Mirescu, C., Basu, K., Cheewatrakoolpong, B., DeMong, D. E., Ellis, J. M., Hyde, L. A., Lin, Y., Markgraf, C. G., Mei, H., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227587 · Cited by 305
Rab10 GTPase regulates ER dynamics and morphology
English, A. R., & Voeltz, G. K. (2013) · Nature Cell Biology · doi:10.1038/ncb2647 · Cited by 224
Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats
Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S., & West, A. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403215111 · Cited by 223
Daher, J. P. L., Abdelmotilib, H. A., Hu, X., Volpicelli-Daley, L. A., Moehle, M. S., Fraser, K. B., Needle, E., Chen, Y., Steyn, S. J., Galatsis, P., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.660001 · Cited by 210
Evolving basic, pathological and clinical concepts in PD
Kalia, L. V., & Lang, A. E. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.249 · Cited by 206
Oueslati, A., Schneider, B. L., Aebischer, P., & Lashuel, H. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309991110 · Cited by 203
Ser(P)‐1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease
Fraser, K. B., Rawlins, A. B., Clark, R. G., Alcalay, R. N., Standaert, D. G., Liu, N., Parkinson's Disease Biomarker Program Consortium, & West, A. B. (2016) · Movement Disorders · doi:10.1002/mds.26686 · Cited by 196
Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease
Sanders, L. H., McCoy, J., Hu, X., Mastroberardino, P. G., Dickinson, B. C., Chang, C. J., Chu, C. T., Van Houten, B., & Greenamyre, J. T. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.014 · Cited by 191
Self-citationshRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
Zharikov, A. D., Cannon, J. R., Tapias, V., Bai, Q., Horowitz, M. P., Shah, V., El Ayadi, A., Hastings, T. G., Greenamyre, J. T., & Burton, E. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci64502 · Cited by 186
Self-citationG2019S-LRRK2 Expression Augments -Synuclein Sequestration into Inclusions in Neurons
Volpicelli-Daley, L. A., Abdelmotilib, H., Liu, Z., Stoyka, L., Daher, J. P. L., Milnerwood, A. J., Unni, V. K., Hirst, W. D., Yue, Z., Zhao, H. T., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3642-15.2016 · Cited by 185
A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets
Li, Z., Schulze, R. J., Weller, S. G., Krueger, E. W., Schott, M. B., Zhang, X., Casey, C. A., Liu, J., Stöckli, J., James, D. E., et al. (2016) · Science Advances · doi:10.1126/sciadv.1601470 · Cited by 179
Lessons from the rotenone model of Parkinson's disease
Greenamyre, J. T., Cannon, J. R., Drolet, R., & Mastroberardino, P.-G. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.12.006 · Cited by 166
Self-citationLi, X., Wang, Q. J., Pan, N., Lee, S., Zhao, Y., Chait, B. T., & Yue, Z. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017153 · Cited by 164
Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson’s disease
Ulusoy, A., Decressac, M., Kirik, D., & Björklund, A. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84005-1 · Cited by 155
Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2
Csányi, G., Cifuentes-Pagano, E., Al Ghouleh, I., Ranayhossaini, D. J., Egaña, L., Lopes, L. R., Jackson, H. M., Kelley, E. E., & Pagano, P. J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.025 · Cited by 131
Innate and adaptive immune responses in Parkinson's disease
Schonhoff, A. M., Williams, G. P., Wallen, Z. D., Standaert, D. G., & Harms, A. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.006 · Cited by 124
Thirstrup, K., Dächsel, J. C., Oppermann, F. S., Williamson, D. S., Smith, G. P., Fog, K., & Christensen, K. V. (2017) · Scientific Reports · doi:10.1038/s41598-017-10501-z · Cited by 105
Nox2 as a potential target of mitochondrial superoxide and its role in endothelial oxidative stress
Nazarewicz, R. R., Dikalova, A., Bikineyeva, A. T., & Dikalov, S. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00063.2013 · Cited by 102
14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening
Lavalley, N. J., Slone, S. R., Ding, H., West, A. B., & Yacoubian, T. A. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv453 · Cited by 92
Direct detection of alpha synuclein oligomers in vivo
Dimant, H., Kalia, S. K., Kalia, L. V., Zhu, L., Kibuuka, L. N., Ebrahimi‐Fakhari, D., McFarland, N. R., Fan, Z., Hyman, B. T., & McLean, P. J. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-6 · Cited by 77
Dikalov, S., Li, W., Doughan, A. K., Blanco, R. R., & Zafari, A. M. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00842.2010 · Cited by 76
Li, X., Moore, D. J., Xiong, Y., Dawson, T. M., & Dawson, V. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127639 · Cited by 64
Rab3a and Rab10 are regulators of lysosome exocytosis and plasma membrane repair
Vieira, O. V. (2016) · Small GTPases · doi:10.1080/21541248.2016.1235004 · Cited by 60
Kleinknecht, A., Popova, B., Lázaro, D. F., Pinho, R., Valerius, O., Outeiro, T. F., & Braus, G. H. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006098 · Cited by 58
Mamais, A., Chia, R., Beilina, A. G., Hauser, D. N., Hall, C., Lewis, P. A., Cookson, M., & Bandopadhyay, R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.528463 · Cited by 45
Cited by
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,019
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
Mifflin, L., Ofengeim, D., & Yuan, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0071-y · Cited by 479
LRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Pang, S. Y.-Y., Ho, P. W.-L., Liu, H.-F., Leung, C.-T., Li, L., Chang, E. E. S., Ramsden, D. B., & Ho, S.-L. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0165-9 · Cited by 427
Metadata
- Authors
- Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., Kofler, J. K., Burton, E. A., Alessi, D. R., Hastings, T. G., & Greenamyre, J. T.
- Venue
- Science Translational Medicine
- Published
- 2018-07-25
- Volume
- 10
- Issue
- 451
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883053634
- Cited by
- 564
- References
- 38
- FWCI
- 39.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.